True Wealth Design’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

True Wealth Design’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-484	Closed	-$63.9K	–	2875
2025 Q1	$63.9K	Buy	484 +2	+0.4%	+$249	0.02%	154
2024 Q4	$40.3K	Buy	482 +48	+11%	+$3.94K	0.02%	205
2024 Q3	$31.8K	Buy	+434	New	+$32.6K	0.01%	229

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

True Wealth Design's ITCI Position: Q2 2025 in Review

True Wealth Design sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 484 shares — an estimated $63.9K sold.

True Wealth Design first reported a position in ITCI in Q3 2024 and held it in 3 quarters. The position peaked at $63.9K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

True Wealth Design reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
True Wealth Design sold 484 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $63.9K.
True Wealth Design first reported a position in Intra-Cellular Therapies Inc. in Q3 2024 and held it in 3 quarters.
True Wealth Design's Intra-Cellular Therapies Inc. position peaked at $63.9K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on True Wealth Design's 13F filing for Q2 2025, filed 6 Aug 2025.